Publication:
Zoledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized clinical study

Simple item page
dc.contributor.authorAtahan, Lale
dc.contributor.authorYıldız, Ferah
dc.contributor.authorCengiz, Mustafa
dc.contributor.authorKaplan, Bünyamin
dc.contributor.authorÖzkan, Metin
dc.contributor.authorYazıcı, Gözde
dc.contributor.authorGündoğ, Mete
dc.contributor.authorHaydaroğlu, Ayfer
dc.contributor.authorKorcum, Aylin Fidan
dc.contributor.authorŞengöz, Meriç
dc.contributor.authorDinçer, Maktav
dc.contributor.authorAkmansu, Müge
dc.contributor.authorHayran, Mutlu
dc.contributor.buuauthorEngin, Kayıhan
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentRadyasyon Onkolojisi Ana Bilim Dalı
dc.contributor.scopusid6701768798
dc.date.accessioned2022-09-08T07:59:24Z
dc.date.available2022-09-08T07:59:24Z
dc.date.issued2010-06
dc.description.abstractIn this prospective study, the efficacy and safety of radiotherapy combined with zoledronic acid was evaluated. Breast cancer patients with painful bone metastases were randomized to either high- or reduced-dose radiotherapy. All patients received zoledronic acid (4 mg) every 28 days from the beginning of radiotherapy. Analgesic and pain scores in addition to visual analog score (VAS) for treatment satisfaction and whole-body bone scintigraphy were evaluated. No significant differences could be found in analgesic or pain scores and bone scintigraphy results between the groups. Our results suggest that reduced-dose radiotherapy produces similar response rates and response durations when used concomitantly with zoledronic acid.
dc.identifier.citationAtahan, L. vd. (2010). "Zoledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized clinical study". Supportive Care in Cancer, 18(6), 691-698.
dc.identifier.endpage698
dc.identifier.issn0941-4355
dc.identifier.issn1433-7339
dc.identifier.issue6
dc.identifier.pubmed19484483
dc.identifier.scopus2-s2.0-77953621327
dc.identifier.startpage691
dc.identifier.urihttps://doi.org/10.1007/s00520-009-0663-x
dc.identifier.urihttps://link.springer.com/article/10.1007/s00520-009-0663-x
dc.identifier.urihttp://hdl.handle.net/11452/28552
dc.identifier.volume18
dc.identifier.wos000277942800005
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherSpringer
dc.relation.collaborationYurt içi
dc.relation.collaborationSanayi
dc.relation.journalSupportive Care in Cancer
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBone metastasis
dc.subjectBreast cancer
dc.subjectRadiotherapy
dc.subjectZoledronic acid
dc.subjectIn-vitro
dc.subjectSkeletal complications
dc.subjectMultifraction radiotherapy
dc.subjectBisphosphonates inhibit
dc.subjectTrial
dc.subjectCarcinoma
dc.subjectCells
dc.subjectApoptosis
dc.subjectAdhesion
dc.subjectSingle
dc.subjectOncology
dc.subjectHealth care sciences & services
dc.subjectRehabilitation
dc.subject.emtreeAlkaline phosphatase
dc.subject.emtreeZoledronic acid
dc.subject.emtreeBisphosphonic acid derivative
dc.subject.emtreeBone density conservation agent
dc.subject.emtreeImidazole derivative
dc.subject.emtreeZoledronic acid
dc.subject.emtreeAdult
dc.subject.emtreeAged
dc.subject.emtreeAlkaline phosphatase blood level
dc.subject.emtreeArticle
dc.subject.emtreeBone metastasis
dc.subject.emtreeBone scintiscanning
dc.subject.emtreeBreast cancer
dc.subject.emtreeCancer chemotherapy
dc.subject.emtreeCancer palliative therapy
dc.subject.emtreeCancer patient
dc.subject.emtreeCancer radiotherapy
dc.subject.emtreeClinical effectiveness
dc.subject.emtreeClinical study
dc.subject.emtreeClinical trial
dc.subject.emtreeDiarrhea
dc.subject.emtreeDyspepsia
dc.subject.emtreeFemale
dc.subject.emtreeFlu like syndrome
dc.subject.emtreeHuman
dc.subject.emtreeMajor clinical study
dc.subject.emtreeMultimodality cancer therapy
dc.subject.emtreeNausea
dc.subject.emtreeNuclear magnetic resonance imaging
dc.subject.emtreeOutcome assessment
dc.subject.emtreePain assessment
dc.subject.emtreePatient safety
dc.subject.emtreePatient satisfaction
dc.subject.emtreePhase 4 clinical trial
dc.subject.emtreePriority journal
dc.subject.emtreeRadiation dose
dc.subject.emtreeTreatment response
dc.subject.emtreeUrinary tract infection
dc.subject.emtreeVisual analog scale
dc.subject.emtreeWhole body scintiscanning
dc.subject.emtreeBone neoplasms
dc.subject.emtreeBreast neoplasms
dc.subject.emtreeControlled study
dc.subject.emtreeKaplan Meier method
dc.subject.emtreeMiddle aged
dc.subject.emtreeMultimodality cancer therapy
dc.subject.emtreePain measurement
dc.subject.emtreePalliative therapy
dc.subject.emtreePathology
dc.subject.emtreeRandomized controlled trial
dc.subject.emtreeSecondary
dc.subject.emtreeVery elderly
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshBone density conservation agents
dc.subject.meshBone neoplasms
dc.subject.meshBreast neoplasms
dc.subject.meshCombined modality therapy
dc.subject.meshDiphosphonates
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshImidazoles
dc.subject.meshKaplan-Meiers estimate
dc.subject.meshMiddle aged
dc.subject.meshPain measurement
dc.subject.meshPalliative care
dc.subject.meshRadiotherapy dosage
dc.subject.scopusZoledronic Acid; Bone Metastasis; Bisphosphonic Acid Derivative
dc.subject.wosOncology
dc.subject.wosHealth care sciences & services
dc.subject.wosRehabilitation
dc.titleZoledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized clinical study
dc.typeArticle
dc.wos.quartileQ2 (Health care sciences & services)
dc.wos.quartileQ3 (Oncology)
dc.wos.quartileQ1 (Rehabilitation)
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Radyasyon Onkolojisi Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

İndeksli Yayınlar / Indexed Publications